Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued

By Naomi Pearce | Apr 20, 2022

Read more

We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the Federal Court found certain batches of Juno’s generic parecoxib produ...
Biogen completes the sale of its stake in the Samsung Bioepis joint venture

By Bioblast Editor | Apr 20, 2022

Read more

Biogen reported that it has completed the sale of its stake in the Samsung Bioepis joint venture to Samsung Biologics. In January 2022 Biogen announced that it would sell its stake in Samsung Bioepis for an aggregate consideration of up to USD $2.3 billion.
Artificial intelligence cannot be a patent inventor

By Naomi Pearce | Apr 20, 2022

Read more

Commissioner of Patents v Thaler [2022] FCAFC 62

Date:

Court:

Judges:

13 April 2022

Full Court of the Federal Court of Austral...
Pearce IP BioBlast w/e 15 April 2022

By Naomi Pearce | Apr 19, 2022

Read more

11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved in C...
The Full Federal Court overturns AI inventorship in Australia

By Pearce IP | Apr 19, 2022

Read more

An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by confirming that artificial intelligence (AI) cannot be named as ...
Amgen releases preliminary results from its Ph III study of ABP654 (proposed ustekinumab biosimilar)

By Bioblast Editor | Apr 18, 2022

Read more

Amgen released preliminary results from its Ph III study of ABP654 (proposed ustekinumab biosimilar) in adults with severe plaque psoriasis. Amgen reported that the study met the primary efficacy endpoint, and that the safety profile of ABP654 was comparable to STELARA®.
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap

By Naomi Pearce | Apr 14, 2022

Read more

In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA from threatening patent infringement proceedings against UbiPark...
AstraZeneca presents initial data from Ph II trial of durvalumab and tremelimumab in ovarian cancer

By Bioblast Editor | Apr 14, 2022

Read more

Cancer Network reported that initial data from AstraZeneca’s Ph II trial of durvalumab and tremelimumab in combination with chemotherapy as neoadjuvant therapy for patients with advanced-stage ovarian cancer was presented at the AACR meeting. The results suggest that more ...
BIOJAMP launches SIMLANDI™/AVT02 high-concentration, low volume, citrate-free biosimilar adalimumab) in Canada

By Bioblast Editor | Apr 14, 2022

Read more

BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free biosimilar adalimumab) in Canada. JAMP Pharma has exclusive commercialisation rights to Alvotech’s AVT02 in Canada in accordance with their January 2020 agreement.
Our 2022 Client Survey Results are in!

By Naomi Pearce | Apr 13, 2022

Read more

Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey.
The responses we received included clients providing over 45% of Pearce IP’...